Molecular docking, synthesis, and cytotoxic evaluation of novel quinazoline-quinazolinone hybrid compounds

Majid Azarmi , Saman Rahimi, Maryam Hormozi, Rezvan Rezaeinasab

Abstract


Background and purpose: Cancer represents a significant public health challenge and a leading cause of mortality globally. Quinazolinones represent a class of privileged structures that exhibit a broad spectrum of biological activities such as anticancer, antihypertensive, antifungal, antibacterial, and anti-inflammatory properties. In the present study, the synthesis of quinazoline-quinazolinone hybrids as anticancer agents and their cytotoxic evaluation are reported.

Experimental approach: Initial studies were done by molecular docking of five analogs of quinazoline-quinazolinone hybrids, erlotinib, and doxorubicin against the epidermal growth factor receptor. Treatment of 3-amino quinazolinone with 4-chloro-2-phenylquinazoline afforded final compounds by the nucleophilic substitution of the chloride with the amine of 3-amino quinazolinone derivatives. The cytotoxic effects of the final compounds were determined in vitro against the MCF-7 cell line using the MTT assay.

Findings/Results: Compound 5b (7-hydroxy-2-methyl-3-(2-phenylquinazolin-4-ylamino) quinazolin-4(3H)-one) showed the highest docking score of -10.1 kcal/mol. Additionally, compound 5d (2-methyl-7-nitro-3-(2-phenylquinazolin-4-ylamino) quinazolin-4(3H)-one) exhibited remarkable in-vitro cytotoxic activity at                       100 µM against the MCF-7 cells.

Conclusion and implications: In the present study, quinazoline-quinazolinone hybrids were synthesized, and their cytotoxic effects on the MCF-7 cell line were evaluated. Among them, compound 5d exhibited the most significant cytotoxic activity. The insertion of a nitro group at the 7 position of quinazolinone enhanced the cytotoxic efficacy against MCF-7 cells, likely attributable to electronic influences. Consequently, this compound could serve as a lead compound in the search for new classes of effective anticancer agents.

 


Keywords


Cytotoxic activity; Hybrid; Molecular docking; Quinazoline; Quinazolinone; Synthesis.

Full Text:

PDF

References


Hawata MA, El-Sayed WA, Nossier ES, Abdel-Rahman AAH. Synthesis and cytotoxic activity of new pyrimido[1,2-c]quinazolines, [1,2,4]triazolo[4,3-c]quinazolines and (quinazolin-4-yl)-1H-pyrazoles hybrids. Biointerface Res Appl Chem. 2022;12:5217-5233. DOI: 10.33263/BRIAC124.52175233.

Keikhosravi N, Dehghan-Ghahfarokhi E, Abdollahi S, Piramoon M, Ghasemian-Yadegari J, Rezaeinasab R. Solvent-free synthesis and antimicrobial activity of dihydroquinazolinone derivatives. J Med Chem Sci. 2022;5:308-314. DOI: 10.26655/JMCHEMSCI.2022.3.3.

El-Shershaby MH, Bayoumi AH, Ghiaty A, Abulkhair HS. Synthesis and pharmacological evaluation of some new 1,2,4-triazolo quinazoline derivatives. Az J Pharm Sci. 2021;64:69-79. DOI: 10.21608/ajps.2021.187755.

Alqahtani AS, Ghorab MM, Nasr FA, Ahmed MZ, Al Mishari AA, Attia SM. et al. Cytotoxicity of newly synthesized quinazoline-sulfonamide derivatives in human leukemia cell lines and their effect on hematopoiesis in zebrafish embryos. Int J Mol Sci. 2022;23:4720,1-17. DOI: 10.3390/ijms23094720.

Mphahlele MJ, Maluleka MM, Aro A, McGaw LJ, Choong YS. Benzofuran-appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies. J Enzyme Inhib Med Chem. 2018;33:1516-1528.DOI: 10.1080/14756366.2018.1510919.

Banerji B, Chandrasekhar K, Sreenath K, Roy S, Nag S, Saha KD. Synthesis of triazole-substituted quinazoline hybrids for anticancer activity and a lead compound as the EGFR blocker and ROS inducer agent. ACS Omega. 2018;3:16134-16142. DOI: 10.1021/acsomega.8b01960. Epub 2018 Nov 28.

Cheng W, Wang S, Yang Z, Tian X, Hu Y. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia. Drug Des Devel Ther. 2019;13:3079-3089. DOI: 10.2147/DDDT.S209481.

Seydbagian N, Dehghan-Ghahfarokhi E, Abdollahi S, Rezaeinasab R. Synthesis, antimicrobial activity and molecular docking study of novel N,2-diphenylquinazolin-4-amine derivatives. Iran J Pharm Sci. 2023:19(1):1-10. DOI: 10.22037/ijps.v19i1.43111.

Wu WY, Cao SL, Mao BB, Liao J, Li ZF, Song HB, et al. Synthesis and antiproliferative evaluation of hybrids of indolin-2-one and quinazoline-4(3H)-one linked via imine bond. Lett Drug Des Discov. 2013;10:61-66. DOI: 10.2174/1570180811309010061.

Bathula R, Mondal P, Raparla R, Satla SR. Evaluation of antitumor potential of synthesized novel 2-substituted 4- anilinoquinazolines as quinazoline-pyrrole hybrids in MCF-7 human breast cancer cell line and A-549 human lung adenocarcinoma cell lines. Futur J Pharm Sci. 2020;6:1-11. DOI: 10.1186/s43094-020-00059-5.

Hassanzadeh F, Sadeghi-aliabadi H, Nikooei S, Jafari E, Vaseghi G. Synthesis and cytotoxic evaluation of some derivatives of triazolequinazolinone hybrids. Res Pharm Sci. 2019;14:130-137. DOI: 10.4103/1735-5362.253360.

Noser AA, El-Naggar M, Donia T, Abdelmonsef AH. Synthesis, in silico and in vitro assessment of new quinazolinones as anticancer agents via potential AKT Inhibition. Molecules. 2020,25:4780. DOI: 10.3390/molecules25204780.

Emami L, Sabet R, Khabnadideh S, Faghih Z, Thayori P. Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies. Res Pharm Sci. 2021;16(5):528-546. DOI: 10.4103/1735-5362.323919.

Zare S, Emami L, Faghih Z, Zargari F, Faghih Z, Khabnadideh S. Design, synthesis, computational study and cytotoxic evaluation of some new quinazoline derivatives containing pyrimidine moiety. Sci Rep. 2023,1314461. DOI: 10.1038/s41598-023-41530-6.

Naeem S, Akhtar S, Zafar, Iqbal S. In-silico determination of pKa and logp values of some isoniazid synthetic analogues using Marvin software. Pak J Pharm Sci. 2020;33(2):715-719. DOI: 10.36721/PJPS.2020.33.2.REG.715-719.1.

Nasab RR, Mansourian M, Hassanzadeh F. Synthesis, antimicrobial evaluation and docking studies of some novel quinazolinone Schiff base derivatives. Res Pharm Sci. 2018;13(3):213-220.DOI: 10.4103/1735-5362.228942.

Li W, Chen SY, Hu WN, Zhu M, Liu JM, Fu YH, et al. Design, synthesis, and biological evaluation of quinazoline derivatives containing piperazine moieties as antitumor agents. J Chem Res. 2020;44:536-542. DOI: 10.1177/1747519820910384.

Hassanzadeh F, Sadeghi-Aliabadi H, Jafari E, Sharifzadeh A, Dana N. Synthesis and cytotoxic evaluation of some quinazolinone- 5-(4-chlorophenyl) 1, 3, 4-oxadiazole conjugates. Res Pharm Sci. 2019;14:408-413. DOI: 10.4103/1735-5362.268201.

Wu X, Li M, Tang W, Zheng Y, Lian J, Xu L, et al. Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives. Chem Biol Drug Des. 2011;78: 932-940. DOI: 10.1111/j.1747-0285.2011.01234.x.

Wang XM, Xin MH, Xu J, Kang BR, Li Y, Lu SM. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo. Eur J Med Chem. 2015;96:382-395. DOI: 10.1016/j.ejmech.2015.04.037. Epub 2015 Apr 17.

Mortazavi M, Eskandari M, Moosavi F, Damghani T, Khoshneviszadeh M, Pirhadi S, et al. Novel quinazoline‑1,2,3‑triazole hybrids with anticancer and MET kinase targeting properties. Sci Rep. 2023;13:14685. DOI: 10.1038/s41598-023-41283-2.

Sonousi A, Hassan RA, Osman EO, Abdou AM, Emam SH. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity. J Enzyme Inhib Med Chem. 2022; 37:2644-2659. DOI: 10.1080/14756366.2022.2118735.

Abu-Hashem AA, Hakami O, Amri N. Synthesis, anticancer activity and molecular docking of new quinolines, quinazolines and 1,2,4-triazoles with pyrido[2,3-d] pyrimidines. Heliyon. 2024;10:e26735. DOI: 10.1016/j.heliyon.2024.e26735.

Nasab RR, Karami B, Khodabakhshi S. Selective solvent-free Biginelli condensation using tungstate sulfuric acid as powerful and reusable catalyst. Bull Chem React Eng Catal. 2014;9:148-154. DOI: 10.9767/bcrec.9.2.6794.148-154.

Rezaeinasab R, Jafari E, Khodarahmi G. Quinazolinone-based hybrids with diverse biological activities: A mini-review. J Res Med Sci. 2022;27:68. DOI: 10.4103/jrms.jrms_1025_21.

Nasab RR, Hassanzadeh F, Khodarahmi GA, Mirzaei M, Rostami M, Jahanian-Najaf Abadi A. Synthesis, characterization, cytotoxic screening, and density functional theory studies of new derivatives of quinazolin-4(3H)-one Schiff bases. Res Pharm Sci. 2017;12:444-455. DOI: 10.4103/1735-5362.217425.

Masoudinia S, Samadizadeh M, Safavi M, Bijanzadeh HR, Foroumadi A. Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations. BMC Chemistry. 2024;18:30. DOI: 10.1186/s13065-024-01119-0.

Perez-Fehrmann M, Kesternich V, Puelles A, Quezada V, Salazar F, Christen P, et al. Synthesis, antitumor activity, 3D-QSAR and molecular docking studies of new iodinated 4-(3H)-quinazolinones 3N-substituted. RSC Adv. 2022;12:21340. DOI: 10.1039/d2ra03684c.

Kciuk M, Gieleci´nska A, Mujwar S, Kołat D, Kałuzi ´nska-Kołat Z, Celik I, et al. Doxorubicin, an agent with multiple mechanisms of anticancer activity. Cells. 2023;12:659. DOI: 10.3390/cells12040659.

Ahmed MF, Magdy N. Design, synthesis and biological evaluation of some novel substituted quinazoline derivatives as antitumor agents. Acta Pol Pharm. 2018;75:669-677.DOI: 10.1016/j.ejmech.2014.04.029.

Malhotra A, Bansal R, Halim CE, Yap CT, Sethi G, Kumar AP, et al. Novel amide analogues of quinazoline carboxylate display selective anti-proliferative activity and potent EGFR inhibition.

Med Chem Res. 2020;29:2112-2122. DOI: 10.1007/s00044-020-02634-0.

Rafian-boroujeni M, Rezaeinasab R, Bahrami N. One-pot synthesis, cytotoxic evaluation and molecular docking of 3,4,7,8-tetrahydroquinazoline-2,5-(1H,6H)-dione derivatives on EGFR. Int Pharm Acta. 2022;5(1):e5.DOI: 10.22037/ipa.v5i1.38025.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.